Despite bonds offering high yields, their prices have fallen, dragging down traditional 60/40 portfolios. Investors are increasingly turning to managed futures ETFs, which can short bonds and diversify by trading currencies, commodities, and interest rates. These funds have shown strong gains this year, offering a potential hedge when both stocks and bonds decline together. However, they come with higher fees, tax complexities, and performance variability, making them suitable as a modest defensive allocation rather than a full replacement for bonds.
The story on shifts away from the 60/40 portfolio provides context for market breadth and asset moves on Pluang. As of Oct 15, 2026 00:22 WIB, out of 150 US stocks priced on Pluang, 39 rose while 111 fell. Among notable movers, SNAP fell 6.32% with a 63% buy order activity, contrasting with ASX which dropped 6.24% amid 94% sell orders, and KGC declined 5.97% but saw 90% buy orders, reflecting varied investor interest across these assets.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
